India News | J&J Applies for Approval to Conduct Clinical Trials on Adolescents in India

New Delhi [India], August 20 (ANI): US pharma giant Johnson & Johnson has moved an application before the Central Drugs Standard Control Organisation (CDSCO) in India, seeking permission to conduct clinical trials of its single-dose Janssen vaccine against COVID-19 on adolescents (children of age group 12-17 years).

Earlier in August, Johnson & Johnson's was given emergency use approval in India for its single-dose COVID-19 vaccine.

Also Read | Bengaluru Woman Ends Life by Hanging Self at Home After Friends Fail To Return Rs 9 Lakh.

A statement by Johnson & Johnson read, "On August 17, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12 - 17 years."

"To ultimately achieve herd immunity, it is imperative that COVID-19 vaccine clinical trials continue to move forward in this population, and we remain deeply committed to the critical work needed to make our COVID-19 vaccine equitably accessible for all age groups," the company's spokesperson said.

Also Read | OnePlus 9 RT With Android 12 Likely To Be Launched in October 2021: Report.

The five vaccines which were granted emergency use authorisation in India are Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V m, Moderna and Now Johnson & Johnson (J&J). (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)